{
    "clinical_study": {
        "@rank": "75582", 
        "arm_group": [
            {
                "arm_group_label": "Fluconazole", 
                "arm_group_type": "Experimental", 
                "description": "Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days."
            }, 
            {
                "arm_group_label": "Meglumine Antimoniate", 
                "arm_group_type": "Active Comparator", 
                "description": "Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the therapeutic response to fluconazole in patients\n      with cutaneous leishmaniasis caused by and L.(V.)guyanensis and L.(V.) braziliensis."
        }, 
        "brief_title": "High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cutaneous Leishmaniasis", 
        "condition_browse": {
            "mesh_term": [
                "Leishmaniasis", 
                "Leishmaniasis, Cutaneous"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and   a\n             positive culture or diagnosed by polymerase chain reaction (PCR) methods or by\n             intradermal skin testing (Montenegro test).\n\n          -  Number of lesions: 1 to 3 ulcerative lesions.\n\n          -  Lesion\u00b4s diameter: 1 to 5 cm.\n\n          -  Disease duration: up to three months.\n\n        Exclusion Criteria:\n\n          -  Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)\n\n          -  Immunodeficiency or antibody to HIV\n\n          -  Any non-compensated or uncontrolled condition, such as active tuberculosis,\n             malignant disease, severe malaria, HIV, or other major infectious diseases\n\n          -  Lactation, pregnancy (to be determined by adequate test) or inadequate contraception\n             in females of childbearing potential for treatment period plus 2 months\n\n               -  Lack of suitability for the trial:\n\n          -  Negative parasitology (aspirate/biopsy/PCR)or negative Montenegro test\n\n          -  Any history of prior anti-leishmania therapy\n\n          -  Any condition which compromises ability to comply with the study procedures\n\n               -  Administrative reasons:\n\n          -  Lack of ability or willingness to give informed consent (patient and/or parent /\n             legal representative)\n\n          -  Anticipated non-availability for study visits/procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953744", 
            "org_study_id": "FlucoLBrBaMa"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fluconazole", 
                "description": "Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.", 
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Meglumine Antimoniate", 
                "description": "Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.", 
                "intervention_name": "Meglumine Antimoniate", 
                "intervention_type": "Drug", 
                "other_name": "Glucantime"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Meglumine antimoniate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fluconazole; Meglumine antimoniate;L.Braziliensis;", 
            "L.Guyanensis"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "contact": {
                "email": "mayradourado@hotmail.com", 
                "last_name": "Mayra Dourado", 
                "phone": "55-73-35535092"
            }, 
            "contact_backup": {
                "email": "ednaldo-lago@ig.com.br", 
                "last_name": "Ednaldo Lago", 
                "phone": "55-73-35535092"
            }, 
            "facility": {
                "address": {
                    "city": "Presidente Tancredo Neves", 
                    "country": "Brazil", 
                    "state": "Bahia", 
                    "zip": "45416000"
                }, 
                "name": "Posto de Sa\u00fade de Corte de Pedra"
            }, 
            "investigator": [
                {
                    "last_name": "Silvana Concei\u00e7\u00e3o da Silva, Biologist", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mayra Elizabeth Dourado, Nurse", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maria das Gra\u00e7as Brito, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Luiz Henrique Guimar\u00e3es, Doctor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis", 
        "overall_contact": {
            "email": "prlmachado@hotmail.com", 
            "last_name": "Paulo Roberto MD Lima Machado, PhD", 
            "phone": "55-71-3237735"
        }, 
        "overall_contact_backup": {
            "email": "aschriefer@globo.com", 
            "last_name": "Nicolaus Albert MD Borges Schriefer", 
            "phone": "55-71-32455493"
        }, 
        "overall_official": {
            "affiliation": "University of Bahia", 
            "last_name": "Paulo Roberto Lima Machado, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients.", 
            "measure": "Cure rate or complete cicatrization of the ulcer.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953744"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universit\u00e1rio Professor Edgard Santos", 
            "investigator_full_name": "Paulo Roberto Lima Machado", 
            "investigator_title": "Associate Researcher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients.", 
            "measure": "Initial cure rate or complete cicatrization of the ulcer", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "Hospital Universit\u00e1rio Professor Edgard Santos", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Federal University of Bahia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hospital Universit\u00e1rio Professor Edgard Santos", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}